Literature DB >> 2029496

Specificity of the low density lipoprotein-glycosaminoglycan interaction.

T Sambandam1, J R Baker, J E Christner, S L Ekborg.   

Abstract

There is ample documentation of the binding of chondroitin sulfate/dermatan sulfate proteoglycans to low density lipoprotein (LDL) both in vivo and in vitro. The interaction of these two species may be an early and important step in atherogenesis. Therefore, there is interest in defining the features of both molecules that are critical for their interaction. We employed a recently described competitive microassay that measures initial binding of proteoglycan to immobilized LDL. We confirmed the work of others that it is the apolipoprotein B component and, at least in part, a heparin-binding domain of LDL that are responsible for binding chondroitin sulfate/dermatan sulfate proteoglycans. The principal thrust of our study was concerned with the effects of a glycosaminoglycan's degree of sulfation on the binding to LDL. Initial experiments comparing dermatan sulfate and chondroitin sulfate proteoglycans indicated that the former was more efficient at binding LDL than the latter and that oversulfation, rather than chain length or iduronate content, was the preeminent feature involved. Additional binding studies with dermatan sulfate, chemically sulfated chondroitin-4-sulfate, and naturally occurring oversulfated chondroitin sulfates indicated that the degree of sulfation, not the position of sulfation, determined affinity for LDL. These results suggest that studies should be undertaken to determine whether oversulfated segments of glycosaminoglycans are especially involved in associations with LDL, leading to lipid accumulation, in the artery wall.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2029496     DOI: 10.1161/01.atv.11.3.561

Source DB:  PubMed          Journal:  Arterioscler Thromb        ISSN: 1049-8834


  9 in total

Review 1.  Constitutive and stimulated macropinocytosis in macrophages: roles in immunity and in the pathogenesis of atherosclerosis.

Authors:  Sasha A Doodnauth; Sergio Grinstein; Michelle E Maxson
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2019-02-04       Impact factor: 6.237

2.  Proteoglycan distribution in lesions of atherosclerosis depends on lesion severity, structural characteristics, and the proximity of platelet-derived growth factor and transforming growth factor-beta.

Authors:  S P Evanko; E W Raines; R Ross; L I Gold; T N Wight
Journal:  Am J Pathol       Date:  1998-02       Impact factor: 4.307

3.  Cholesterol-dependent changes of glycosaminoglycan pattern in human aorta.

Authors:  R Kruse; M Merten; K Yoshida; A Schmidt; W Völker; E Buddecke
Journal:  Basic Res Cardiol       Date:  1996 Sep-Oct       Impact factor: 17.165

Review 4.  A role for proteoglycans in vascular disease.

Authors:  Thomas N Wight
Journal:  Matrix Biol       Date:  2018-02-27       Impact factor: 11.583

5.  Specificity of the hyaluronate lyase of group-B streptococcus toward unsulphated regions of chondroitin sulphate.

Authors:  J R Baker; H Yu; K Morrison; W F Averett; D G Pritchard
Journal:  Biochem J       Date:  1997-10-01       Impact factor: 3.857

Review 6.  Pneumococcal virulence factors: structure and function.

Authors:  M J Jedrzejas
Journal:  Microbiol Mol Biol Rev       Date:  2001-06       Impact factor: 11.056

7.  Early extracellular and cellular lipid deposits in aorta of cholesterol-fed rabbits.

Authors:  J R Guyton; K F Klemp
Journal:  Am J Pathol       Date:  1992-10       Impact factor: 4.307

Review 8.  Smooth Muscle Cell-Proteoglycan-Lipoprotein Interactions as Drivers of Atherosclerosis.

Authors:  Sima Allahverdian; Carleena Ortega; Gordon A Francis
Journal:  Handb Exp Pharmacol       Date:  2022

Review 9.  Glycosaminoglycans: From Vascular Physiology to Tissue Engineering Applications.

Authors:  Antonio Junior Lepedda; Gabriele Nieddu; Marilena Formato; Matthew Brandon Baker; Julia Fernández-Pérez; Lorenzo Moroni
Journal:  Front Chem       Date:  2021-05-18       Impact factor: 5.221

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.